The Nomination Committee proposes two new Board members
1 april, 17:50
The Nomination Committee proposes two new Board members
Vitrolife AB (publ) ("Vitrolife") today announced that its Nomination Committee proposes the election of Nicklas Hansen and David T. Hansen as new Board members. The Committee further proposes the re-election of Jón Sigurdsson as Chairman of the Board, as well as all current Board members except Lars Holmqvist, who has decided not to stand for re-election at the 2026 Annual General Meeting.
Nicklas Hansen is Chief Investment Officer at Vitrolife's largest shareholder, William Demant Invest A/S, where he is responsible for its investment portfolio. He has held several positions at William Demant Invest since joining in 2016 from the Danish Export and Investment Fund. Nicklas currently serves on the Boards of INVISIO A/S and Jeudan A/S, and is a board observer at Vision RT Ltd.
David T. Hansen is currently Chief Executive Officer at Fertio Group, a private equity-owned company focusing on sperm and egg banking. Fertio Group owns European Sperm Bank. Prior to joining Fertio Group in 2024, David founded and held the position of Managing Partner at BlackCap Equity Management, a private equity firm focused on building fertility medtech, embryo diagnostics and fertility clinic assets with institutional investors in the US, Ireland and Asia. Between 2015 and 2021, David served as Chief Executive Officer of Origio and Global President of CooperSurgical Fertility and Genomic Solutions. Prior to that, from 2008 to 2014, he led the global Research Models business at Taconic Biosciences (USA).He also spent twelve years in leadership roles at Novo Nordisk, including serving as Chief Executive Officer of Novo Nordisk Scandinavia AB from 2003 to 2008.
The Nomination Committee proposal entails that the Board shall consist of six members. The Committee's complete proposals are presented in the notice convening Vitrolife's 2026 Annual General Meeting.
The information was submitted for publication, through the agency of the contact persons set out above, at 01-04-2026 17:50 CET.
Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,150 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.
Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.
Jenny Jakobson
Investor Relations
investors@vitrolife.com
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Ämnen i artikeln
The Nomination Committee proposes two new Board members
1 april, 17:50
The Nomination Committee proposes two new Board members
Vitrolife AB (publ) ("Vitrolife") today announced that its Nomination Committee proposes the election of Nicklas Hansen and David T. Hansen as new Board members. The Committee further proposes the re-election of Jón Sigurdsson as Chairman of the Board, as well as all current Board members except Lars Holmqvist, who has decided not to stand for re-election at the 2026 Annual General Meeting.
Nicklas Hansen is Chief Investment Officer at Vitrolife's largest shareholder, William Demant Invest A/S, where he is responsible for its investment portfolio. He has held several positions at William Demant Invest since joining in 2016 from the Danish Export and Investment Fund. Nicklas currently serves on the Boards of INVISIO A/S and Jeudan A/S, and is a board observer at Vision RT Ltd.
David T. Hansen is currently Chief Executive Officer at Fertio Group, a private equity-owned company focusing on sperm and egg banking. Fertio Group owns European Sperm Bank. Prior to joining Fertio Group in 2024, David founded and held the position of Managing Partner at BlackCap Equity Management, a private equity firm focused on building fertility medtech, embryo diagnostics and fertility clinic assets with institutional investors in the US, Ireland and Asia. Between 2015 and 2021, David served as Chief Executive Officer of Origio and Global President of CooperSurgical Fertility and Genomic Solutions. Prior to that, from 2008 to 2014, he led the global Research Models business at Taconic Biosciences (USA).He also spent twelve years in leadership roles at Novo Nordisk, including serving as Chief Executive Officer of Novo Nordisk Scandinavia AB from 2003 to 2008.
The Nomination Committee proposal entails that the Board shall consist of six members. The Committee's complete proposals are presented in the notice convening Vitrolife's 2026 Annual General Meeting.
The information was submitted for publication, through the agency of the contact persons set out above, at 01-04-2026 17:50 CET.
Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,150 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.
Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.
Jenny Jakobson
Investor Relations
investors@vitrolife.com
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Ämnen i artikeln
Analys
Riksdagsvalet 2026
Inflation
Analys
Riksdagsvalet 2026
Inflation
Marknadsöversikt
1 DAG %
Senast
1 mån
